# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001628280-26-045886
Filing Date
2026-06-29
Accepted
2026-06-29 08:12:47
Documents
107
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | repl-20260331.htm iXBRL | 10-K | 1882278
2 | EX-4.3 | exhibit43descriptionofsecu.htm | EX-4.3 | 27847
3 | EX-10.45 | replimunegroupinc-formrest.htm | EX-10.45 | 55512
4 | EX-21.1 | exhibit211_replimunexsubsi.htm | EX-21.1 | 5010
5 | EX-23.1 | replfy26drafpwcconsent_ele.htm | EX-23.1 | 2142
6 | EX-31.1 | repl-20260331x10kxexx311.htm | EX-31.1 | 10135
7 | EX-31.2 | repl-20260331x10kxex312.htm | EX-31.2 | 10128
8 | EX-32.1 | repl-20260331x10kxex321.htm | EX-32.1 | 4771
9 | EX-32.2 | repl-20260331x10kxex322.htm | EX-32.2 | 4765
10 | EX-97 | replimune-clawbackpolicy_e.htm | EX-97 | 48423
16 |  | repl-20260331_g1.jpg | GRAPHIC | 56828
| Complete submission text file | 0001628280-26-045886.txt |  | 9775430

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
11 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | repl-20260331.xsd | EX-101.SCH | 69403
12 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | repl-20260331_cal.xml | EX-101.CAL | 122605
13 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | repl-20260331_def.xml | EX-101.DEF | 316908
14 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | repl-20260331_lab.xml | EX-101.LAB | 872091
15 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | repl-20260331_pre.xml | EX-101.PRE | 612271
111 | EXTRACTED XBRL INSTANCE DOCUMENT | repl-20260331_htm.xml | XML | 1119002

Mailing Address 500 UNICORN PARK WOBURN MA 01801
Business Address 500 UNICORN PARK WOBURN MA 01801 (781) 222-9600
Replimune Group, Inc. (Filer) CIK: 0001737953 (see all company filings)

EIN.: 822082553 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 10-K | Act: 34 | File No.: 001-38596 | Film No.: 261131439
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)